| INTRODUC TI ON
Over the past three decades, the world has witnessed a rapid rise in the prevalence of type 2 diabetes mellitus (T2DM) and expected to have 629 million of diabetes patients with 20-79 years by 2045.
This pandemic of T2DM leads not only to health problem such as diabetic-related complications but also to economic burden which is estimated to be USD 776 billion by 2045 across the globe. 1 An ageing population, changes in lifestyle, dietary patterns, physical inactivity, obesity and stress are the major contributors for the rise in T2DM. Due to the chronic and progressive nature of the disease, undiagnosed or poorly managed T2DM can lead to increased morbidity and mortality.
Despite the availability of several AHAs and addition of new drug classes to the treatment algorithm, more than 50% of patients with T2DM do not achieve glycaemic targets, suggesting an urgent need for treatment strategies focusing on prevention and progression of T2DM and its long-term complications. 2, 3 The updated treatment guidelines (2018) recommend making lifestyle changes in diet and physical activity as part of T2DM management.
Nutrition therapy with individualized meal plan including energy balance, eating patterns and macronutrient distribution and each nutrition is indicated based on patient's age, body weight, physical activity, baseline HbA1c levels and diabetic-related complications. 4 For exercise therapy, patients with T2DM are advised to do 150 min/wk of moderate-to-vigorous-intensity physical activity or 75 min/wk of vigorous-intensity exercise or interval training for a minimum of 3 d/wk to reduce the risk of T2DM-related complications. 4 Landmark studies, which are bases of the guideline, revealed the importance of lifestyle modification including diet and exercise for glycaemic control and prevention of diabetes-related complications. As intervention for diet, the DIRECT study indicated that
Mediterranean and low-carbohydrate diets may be as effective as low-fat diets for glycaemic control. 5 There are several intervention studies focusing on exercise. The IDES study demonstrated that promoting physical activity with aerobic and resistance training improved HbA1c compared to exercise counselling alone. 6 In addition, the Diabetes Prevention Programme study has shown benefits of lifestyle intervention, at least 150 minutes of physical activity per week to achieve a 7% weight loss, in reducing the incidence of T2DM in subjects at risk of diabetes. 7 The Look AHEAD study demonstrated that intensive lifestyle intervention through both decreased caloric intake and increased physical activity focusing on weight loss did not reduce the rate of cardiovascular events in overweight or obese adults T2DM patients while achieved better glycaemic control compared to control group. 8 In the randomized Steno-2 study of 21 years follow-up, multifactorial intervention including lifestyle changes (diet, exercise and weight loss) and pharmacotherapy (control of blood glucose, blood pressure and lipid profile)
has been shown to reduce the risk of not only microvascular but also macrovascular events in T2DM. 9 The benefits of an intensive multifactorial treatment approach on the risk of cerebrovascular events and macrovascular complications were demonstrated in Japanese patients in the J-DOIT3 trial. 10 Among the available oral AHAs, use of incretin-based therapies such as DPP-4 inhibitors has increased recently because of the good glycaemic control with a low risk of hypoglycaemia and weight neutrality associated with these drugs. In Japan, more than 70% of patients with T2DM are being treated with DPP-4 inhibitors and ~60% of drug-naïve patients receive DPP-4 inhibitors as the firstline treatment. 11 In view of recent reports demonstrating positive effects of nutrition and diet on incretin hormones such as GLP-1, 12 we hypothesize an IDEP (Interaction between Diet/Exercise and Pharmacotherapy) concept by comprehensive literature review. The IDEP concept is the active incretin hormone levels, especially GLP-1, can be enriched through modifications in the diet, physical exercise and pharmacotherapy, which is further protected from degradation by use of DPP-4 inhibitors, thereby offers good glycaemic control in patients with T2DM. In this review, we discuss the IDEP concept, focusing on whether diet, exercise and pharmacotherapy can affect GLP-1 secretion. granules, all of which contribute to stimulation of insulin section in a glucose-dependent manner. 14 Incretin effect accounts for approximately 50% to 70% of total insulin secretion in subjects with normal glucose tolerance; however, in patients with T2DM, the incretin effect is diminished and accounts only for 10% to 40% of insulin secretion. Whether or not the decreased incretin effect is due to T2DM itself, or due to decreased β cell function, remains unclear. 15 Of the two incretins, we focused on GLP-1 because it potentiates insulin secretion under hyperglycaemic conditions and reduces blood glucose levels in patients with T2DM along with inhibition of gastric emptying, food intake and glucagon secretion. 16 In addition to improved glycaemic control and preserving islet β cell mass, GLP-1 has demonstrated beneficial effects on such as cardiac function and atherosclerotic plaque. 17 Further, the effect of incretins is dependent on the serum level of the soluble DPP-4 enzyme. In obese patients with T2DM, the plasma DPP-4 activity is increased resulting in reduced incretin effect and thereby decreasing the efficacy of DPP-4 inhibitor therapy. 18, 19 In addition, bariatric surgery aimed at weight loss in individuals with T2DM shown to alter GLP-1 dynamics resulting in improved secretory response to nutrient intake. This improved nutrient sensing could be due to the increased nutrient load into the jejunum, bypassing duodenum, because of the direct connection to the stomach. 20 The maximum utilization of GLP-1 could be achieved by the IDEP concept.
| IN CRE TIN HORMONE S

| ME THOD TO RE TRIE VE ARTI CLE S
We performed a narrative review as we had three topics integrated in one concept. We searched appropriate articles with 
| D IE T THER APY
Diet therapy is important not only as a fundamental treatment for diabetes but as a method to induce GLP-1 which collaborates with pharmacotherapy for better glycaemic control. In the following section, we summarize nutrition, food, dietary patterns and a couple of ways to induce GLP-1 secretion.
| Nutrition that induces GLP-1 secretion
| Carbohydrates
Glucose is a potent stimulus for the secretion of incretin hormones.
Intestinal glucose sensing is mainly facilitated by the sodium-dependent glucose transporter (SGLT1), which is present abundantly in the absorptive enterocytes and the apical membranes of L and K cells. 21 Apart from SGLT1, GLUT2 is essential for glucose sensing and thus plays a role in systemic glucose control. 22 In addition to SGLT1 and GLUT2, secretion of GLP-1 in response to glucose may be mediated, at least in part, by the sweet taste receptors (T1R2 + T1R3) 23 48 and whey protein 49 (Table 2 53 Similarly, bread made from sourdough lowered GLP-1 response when compared with multigrain or sprouted grain bread in subjects at risk for glucose intolerance 54 ( Table 2 ).
| Foods that affect GLP-1 secretion
| Dietary patterns that induce GLP-1 secretion
| Effect of a sequence of a dietary regimen intake on incretin secretion
The type of meal, sequence of meal intake and adjustment in calorie consumption can all play a role in maintaining postprandial glucose homoeostasis. It has been reported that consuming fish/meat before rice enhances GLP-1 secretion compared with consuming rice before fish/meat in both healthy subjects and in patients with T2DM which leads to amelioration of postprandial glucose excursion. 55 Similarly, a whey preload or protein drink before a meal resulted in increased insulin and GLP-1 secretion, and decreased gastric emptying, in patients with T2DM. 56, 57 These results suggest that eating carbohydrates later in a meal after protein might be a good strategy to enhance secretion of GLP-1 and in regulating postprandial glucose.
In patients with T2DM, adjusting the calorie balance in each meal with a high-energy breakfast and low-energy dinner has been shown to increase GLP-1 levels, and decrease prandial hyperglycaemia compared to a high-energy dinner and lower-energy breakfast. 58 Therefore, a change in meal timing with regard to calorie consumption could beneficially modulate GLP-1 secretion.
| Effect of mastication frequency per mouthful and eating speed on incretin secretion
It has been reported that mastication frequency, eating speed and compared with usual eating, without affecting the concentrations of blood glucose or serum insulin. 59 Findings from the Watari Study in Japan showed that eating quickly was significantly associated with metabolic syndrome compared with slow eating. 60 Further, eating the same meal slowly for 30 minutes instead of 5 minutes resulted in higher concentrations of GLP-1 and peptide YY (PYY) levels in healthy subjects. 61 Therefore, eating slowly and chewing more could contribute to induce GLP-1 secretion.
| Effect of intermittent fasting vs continuous energy restriction on glycaemic control and incretin secretion
A recent report revealed that intermittent energy restriction is comparable for the reduction of HbA1c with continuous energy restriction in patients with type 2 diabetes. 62 While a report showed that continuous energy restriction reduced active baseline GLP-1 from baseline, 63 there is few report to reveal the effect of energy restriction on GLP-1 secretion which means further studies are warranted to elucidate effect on GLP-1 secretion in these important dietary interventions.
| E XERCIS E THER APY
| Current situation of exercise therapy for T2DM
Lifestyle modifications, including change in dietary habits and increase in physical activity, are cornerstones for the treatment of T2DM. The effectiveness of exercise, including stretching, aerobic and resistance exercise, depends on the patient's condition such as age, cognitive function and physical activity levels. There is limited evidence on the concrete methods of exercise for optimal glycaemic control and health outcomes, even though adults with T2DM are advised to do these combination exercises. There are some evidence that have shown positive effects of the exercises with several duration time, intensity and methods on glycaemic control. Apart from that, non-exercise activity thermogenesis (NEAT) can be considered as one of the important energy expenditure activities to get a well control of blood glucose. 64 Studies have shown that interrupting prolonged sitting with brief 5 minutes bouts of standing or light-intensity walking can attenuate postprandial increase in glucose levels, insulin, C-peptide and TG responses in patients with T2DM and improve prandial glucose and insulin responses in patients at high risk for T2DM. 65, 66 Furthermore, in patients with T2DM, interval-walking training helped maintain insulin secretion and improve insulin sensitivity and disposition index, in contrast to energy expenditure-matched continuous walking training. 67 The timing of exercise, for example, after a meal was shown to be effective in reducing glucose and TG levels in obese patients with T2DM
who were on standard treatment. The results showed that while resistance exercise before dinner improved postprandial glycaemic control, resistance exercise after dinner improved both postprandial glucose and TG elevation. 68 In addition, a recent report demonstrated that afternoon exercise is more efficacious than morning exercise at improving blood glucose in T2DM individuals. 69 Further, calorie restriction and exercise resulted in weight loss, and improved glucose regulation as well as incretin secretion in obese patients with T2DM, suggesting the beneficial effects of combining diet and exercise therapy. 
| Muscle structure in T2DM
Better understanding of skeletal muscles in terms of type of muscle fibres, size, fibre colour, fatigue resistance, metabolism and insulin 
| Myokine, muscle-derived interleukin-6 (IL-6) induces GLP-1 secretion
Skeletal muscle constitutes 30%−40% of body weight and glucose uptake by the skeletal muscles increases by up to 50-fold during exercise. As exercise-induced glucose uptake involves a complex molecular signalling that is different from insulin, the glucose uptake is preserved even in insulin-resistant muscle emphasizing the therapeutic potential of exercise in the management of chronic metabolic disease. 74 GLUT4 translocation during muscle contraction to sarcolemma and t-tubules is essential for exercise-induced glucose uptake.
Exercise stimulates glucose uptake through enhancing insulin sensitivity and responsiveness. Muscle contraction, muscle remodelling or exercise training produce several secretory factors such as proteins, growth factors and cytokines (also referred to as myokines) that exert beneficial effects of exercise. 75 Although the discovery and validation of myokines are underway, a well-known myokine, IL-6 plays an important role in accelerating glucose uptake independent of insulin and communicating with central and peripheral organs. 76 Both type I and type II fibres express the muscle-derived IL-6 during exercise, which enhances glucose uptake and fat oxidation through activation of AMP-kinase and/or phosphatidylinositol 3-kinase. 77 Findings from several studies reported the benefits of exercise on GLP-1 release ( that, IL-6 levels increased after exercise and GLP-1 and GIP levels remain increased even after 24 hours of exercise, whereas there was no change in prandial insulin or glucagon levels with no effect on prandial glucose levels. Although few studies have examined the association between exercise and GLP-1 secretion, more than 30 minutes exercise with high intensity (more than 70% of ventilator threshold) could be required to increase GLP-1 concentration.
However, more studies are required to elucidate the optimal exercise for T2DM.
| PHARMACOTHER APY
On top of diet and exercise, pharmacotherapy itself is critical to achieve good glycaemic control. In the meantime, there are several medications which induce GLP-1 not only lowering blood glucose level. In the following section, we summarize antihyperglycaemic agents, antidyslipidaemia agents and antihypertensive agents as GLP-1 inducers.
| Antihyperglycaemic agents
| Biguanides
Biguanides are oral medications that reduce plasma glucose via multiple mechanisms. 81 Advantages of metformin include its high efficacy, low cost, minimal hypoglycaemia risk. Gastrointestinal symptom and lactic acidosis are adverse events to be considered.
Several studies demonstrated the involvement of metformin either directly or indirectly in GLP-1 secretion ( 14 wk Active GLP-1↑ Improving insulin resistance metformin affects gut microbiota in diabetic treatment-naive T2DM patients which contributes to metformin's antidiabetic effect. 84 (Table 4 ). (Table 4) .
| α-glucosidase inhibitors
| Thiazolidinediones
Thiazolidinediones (TZDs) are oral medications that increase insulin sensitivity and are of high glucose-lowering efficacy. TZDs are associated with the best evidence among glucose-lowering medications for glycaemic durability. 81 Potential adverse effect of TZDs is regarding fluid retention and congestive heart failure, weight gain and bone fracture.
Insulin resistance is associated with impaired GLP-1 secretion.
Use of pioglitazone improved the insulin resistance developed in rats fed with a high-fat diet as well as increased GLP-1 secretion 92 (Table 4) 
| Sulphonylureas
Sulphonylureas lower glucose by stimulating insulin secretion from pancreatic beta cells. 81 They are inexpensive, widely available and have high glucose-lowering efficacy. As adverse effects, sulphonylureas are associated with weight gain and risk for hypoglycaemia.
Sulphonylurea seems not affect the secretion of incretin.
93
Sulphonylurea could uncouple the glucose dependence of the insulinotropic effect of GLP-1. 
| Antidyslipidaemia agents
There is evidence that the hypolipidaemic agent, atorvastatin, competitively inhibits the DPP-4 enzyme which otherwise inactivates the incretin hormones GLP-1 and GIP. However, this action on DPP-4 inhibition is not class specific, but is structure specific. 95 Another an- 
| IDEP
After reviewing diet, exercise and pharmacotherapy, respectively, we move on to interaction among them. Diet and pharmacotherapy interaction is presented in Table 5 . Nutrient preloads including whey protein before a meal, decreased postprandial glycaemic excursions partly due to the slowing of gastric emptying and the stimulating secretion of the incretins GLP-1 and GIP. In a study with the DPP-4
inhibitor, vildagliptin, whey preload in metformin-treated patients enhanced the efficacy of vildagliptin by slowing gastric emptying and reducing postprandial glycaemia, in addition to increase in plasma intact GLP-1 and GIP. 99 Similarly, in T2DM patients who consumed a preload drink containing 50 g D-xylose, level of prandial glycaemia was reduced and the effect of a DPP-4 inhibitor, sitagliptin, was enhanced. 100 Further, glycaemic control improved in patients with T2DM taking AHAs and eating glutinous brown rice (GBR) for 8 weeks. Moreover, in patients on DPP-4 inhibitor therapy, a significant decrease in glycated haemoglobin (HbA1c) levels and glycoalbumin, in addition to increased active levels of the gut hormones GLP-1 and PYY, were reported, demonstrating additive benefits of GBR. 101 Other than DPP-4 inhibitor therapy, metformin has shown positive effects on GLP-1 levels. It was reported that, mice fed with a HF diet for 12 weeks developed insulin resistance along with increased blood glucose and HbA1c levels, and fasting plasma insulin in conjunction with reduced oral glucose tolerance. However, these effects were reversed with metformin due to improved GLP-1 responses along with reducing prandial plasma free fatty acids. 102 The combination of metformin and a prebiotic oligofructose (OFS) improved fat mass, hepatic TG, and decreased plasma DPP-4 activity and GIP levels in obese rats, thereby improving metabolic outcomes in obesity; however, there was no interactive effect of combining OFS with metformin on GLP-1 secretion. 103 Furthermore, recent study showed that a high-fibre diet improved HbA1c levels as well as increasing GLP-1 AUC in T2DM patients with acarbose and α-glucosidase inhibitors. This could be due to acarbose which transforms some of the starch present in the diet into a fibre thereby reducing its digestion and increasing fermentable carbohydrate in the colon. 104 In Japanese patients with T2DM treated with a DPP-4 inhibitor as monotherapy for 1 year, fat intake, especially saturated fat was shown to be significantly associated with deterioration of HbA1c levels (≥0.4%). 105 There is little evidence regarding exercise and pharmacotherapy interaction. In contrast to the findings demonstrating exercise improves glycaemic and metabolic parameters in patients with T2DM, one study demonstrated that aerobic exercise did not acutely increase total GLP-1 and GIP levels in patients with T2DM, however, metformin treatment, independent of exercise, significantly increased total plasma GLP-1 and GIP concentrations. 106 On the other hand, a 12-week aerobic exercise training programme in obese patients with metabolic syndrome reduced plasma DPP-4 levels, which in turn improved insulin sensitivity and fat oxidation. Therefore, the combination of DPP-4 inhibitors and other AHAs are effective choice for T2DM treatment.
| DISCUSS ION/CON CLUS IONS
Diet, exercise and diabetes education alongside pharmacotherapy are crucial for the optimal management of T2DM. Changing the diet regimen and including exercise intervention as part of T2DM management can improve glycaemic control and reduce treatment escalation of AHAs, which otherwise can lead to risk of developing potential adverse effects and puts excessive costs on health care. 108 The interaction between diet/exercise and pharmacotherapy is limited, and hence we attempted to summarize such studies in the present review. 
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